Search Results - "Canniff, John"

Epigenomic signatures of sarcomatoid differentiation to guide the treatment of renal cell carcinoma by El Zarif, Talal, Semaan, Karl, Eid, Marc, Seo, Ji-Heui, Garinet, Simon, Davidsohn, Matthew P., Sahgal, Pranshu, Fortunato, Brad, Canniff, John, Nassar, Amin H., Abou Alaiwi, Sarah, Bakouny, Ziad, Lakshminarayanan, Gitanjali, Savignano, Hunter, Lyons, Kevin, Matar, Sayed, Ali, Atef, Saad, Eddy, Saliby, Renee Maria, Cordeiro, Paulo, Zhang, Ziwei, El Ahmar, Nourhan, Laimon, Yasmin Nabil, Labaki, Chris, Shah, Valisha, Freeman, Dory, O’Toole, Jillian, Lee, Gwo-Shu Mary, Hwang, Justin, Pomerantz, Mark, Signoretti, Sabina, Van Allen, Eliezer M., Xie, Wanling, Berchuck, Jacob E., Viswanathan, Srinivas R., Braun, David A., Choueiri, Toni K., Freedman, Matthew L., Baca, Sylvan C.

“…Renal cell carcinoma with sarcomatoid differentiation (sRCC) is associated with poor survival and a heightened response to immune checkpoint inhibitors (ICIs)…”
Get full text

Detection of neuroendocrine prostate cancer through plasma-based epigenomic profiling by Eid, Marc, Semaan, Karl, Seo, Ji-Heui, Davidsohn, Matthew P., Fortunato, Brad, Lakshminarayanan, Gitanjali, El Zarif, Talal, Savignano, Hunter, Canniff, John, Saliby, Renee Maria, Saad, Eddy, Pomerantz, Mark, Baca, Sylvan, Freedman, Matthew, Berchuck, Jacob E, Choueiri, Toni K.

“…201 Background: Neuroendocrine prostate cancer (NEPC) is an aggressive resistance phenotype that can develop in men with metastatic prostate adenocarcinoma…”
Get full text

43 Epigenomic profiling of translocation renal cell carcinoma via liquid biopsy by Garinet, Simon, Semaan, Karl, Canniff, John, Phillips, Noa, Davidsohn, Matthew, Berchuck, Jacob, Li, Jiao, Sadagopan, Ananthan, Fortunato, Brad, O’toole, Jillian, Gwo-shu, Mary, Horst, Jack, Freeman, Dory, Seo, Ji-Heui, Freedman, Matthew, Choueiri, Toni, Baca, Sylvan, Viswanathan, Srinivas

“…Abstract Background Translocation renal cell carcinoma (tRCC) is an aggressive subtype of kidney cancer usually driven by a fusion involving the TFE3 gene. Due…”
Get full text

Liquid biopsy epigenomic profiling for cancer subtyping by Baca, Sylvan C., Seo, Ji-Heui, Davidsohn, Matthew P., Fortunato, Brad, Semaan, Karl, Sotudian, Shahabbedin, Lakshminarayanan, Gitanjali, Diossy, Miklos, Qiu, Xintao, El Zarif, Talal, Savignano, Hunter, Canniff, John, Madueke, Ikenna, Saliby, Renee Maria, Zhang, Ziwei, Li, Rong, Jiang, Yijia, Taing, Len, Awad, Mark, Chau, Cindy H., DeCaprio, James A., Figg, William D., Greten, Tim F., Hata, Aaron N., Hodi, F. Stephen, Hughes, Melissa E., Ligon, Keith L., Lin, Nancy, Ng, Kimmie, Oser, Matthew G., Meador, Catherine, Parsons, Heather A., Pomerantz, Mark M., Rajan, Arun, Ritz, Jerome, Thakuria, Manisha, Tolaney, Sara M., Wen, Patrick Y., Long, Henry, Berchuck, Jacob E., Szallasi, Zoltan, Choueiri, Toni K., Freedman, Matthew L.

“…Although circulating tumor DNA (ctDNA) assays are increasingly used to inform clinical decisions in cancer care, they have limited ability to identify the…”
Get full text

Detection of sarcomatoid renal cell carcinoma using plasma cell-free DNA methylation by Semaan, Karl, El Zarif, Talal, Seo, Ji-Heui, Eid, Marc, Canniff, John, Fortunato, Brad, Savignano, Hunter, Davidsohn, Matthew P., Lakshminarayanan, Gitanjali, Saad, Eddy, Saliby, Renee Maria, Bakouny, Ziad, Matar, Sayed, Nuzzo, Pier Vitale, Berchuck, Jacob E, Signoretti, Sabina, Braun, David A., Freedman, Matthew, Baca, Sylvan, Choueiri, Toni K.

“…449 Background: Sarcomatoid differentiation (SD) in renal cell carcinoma (RCC) is associated with poor survival and heightened response to immune checkpoint…”
Get full text

46 Radiological tumor burden is an independent risk factor for survival in patients with metastatic clear cell renal cell carcinoma (mccRCC) treated with first line immunotherapy (IO)-based regimens by Nawfal, Rashad, Eid, Marc, Semaan, Karl, Paul, Morgan A, Saliby, Renee Maria, Chehade, Razane El Hajj, Machaalani, Marc, Phillips, Noa, Canniff, John, Saad, Eddy, Vasseur, Damien, Zarif, Talal El, Yekeduz, Emre, Sun, Maxine, Baca, Sylvan C, Braun, David, Xie, Wanling, Krajewski, Katherine, Choueiri, Toni

“…Abstract Background IO-based regimens (IO + IO or IO + VEGF inhibitor) represent current standard of care systemic therapies for the management of patients…”
Get full text

44 Liquid biopsy epigenomic profiling for the detection of sarcomatoid renal cell carcinoma by Semaan, Karl, Zarif, Talal El, Eid, Marc, Canniff, John, Phillips, Noa, Fortunato, Bard, Savignano, Hunter, Davidson, Matthew P, Chehade, Razane Hajj, Garinet, Simon, Saad, Eddy, Saliby, Renee Maria, Sun, Maxine, Seo, Ji-Heui, Berchuck, Jacob E, Braun, David, Freedman, Matthew L, Choueiri, Toni K, Baca, Sylvan C

“…Abstract Background Sarcomatoid differentiation (SD) in renal cell carcinoma (RCC) is associated with poor survival and heightened response to immune…”
Get full text

Detecting small cell transformation in patients with advanced EGFR mutant lung adenocarcinoma through epigenomic cfDNA profiling by El Zarif, Talal, Meador, Catherine B, Qiu, Xintao, Seo, Ji-Heui, Davidsohn, Matthew P, Savignano, Hunter, Lakshminarayanan, Gitanjali, McClure, Heather M, Canniff, John, Fortunato, Brad, Li, Rong, Banwait, Mandeep K, Semaan, Karl, Eid, Marc, Long, Henry, Hung, Yin P, Mahadevan, Navin R, Barbie, David A, Oser, Matthew G, Piotrowska, Zofia, Choueiri, Toni K, Baca, Sylvan C, Hata, Aaron N, Freedman, Matthew L, Berchuck, Jacob E

“…Histologic transformation to small cell lung cancer (SCLC) is a mechanism of treatment resistance in patients with advanced oncogene-driven lung adenocarcinoma…”
Get full text

Author Correction: Liquid biopsy epigenomic profiling for cancer subtyping by Baca, Sylvan C., Seo, Ji-Heui, Davidsohn, Matthew P., Fortunato, Brad, Semaan, Karl, Sotudian, Shahabbedin, Lakshminarayanan, Gitanjali, Diossy, Miklos, Qiu, Xintao, El Zarif, Talal, Savignano, Hunter, Canniff, John, Madueke, Ikenna, Saliby, Renee Maria, Zhang, Ziwei, Li, Rong, Jiang, Yijia, Taing, Len, Awad, Mark, Chau, Cindy H., DeCaprio, James A., Figg, William D., Greten, Tim F., Hata, Aaron N., Hodi, F. Stephen, Hughes, Melissa E., Ligon, Keith L., Lin, Nancy, Ng, Kimmie, Oser, Matthew G., Meador, Catherine, Parsons, Heather A., Pomerantz, Mark M., Rajan, Arun, Ritz, Jerome, Thakuria, Manisha, Tolaney, Sara M., Wen, Patrick Y., Long, Henry, Berchuck, Jacob E., Szallasi, Zoltan, Choueiri, Toni K., Freedman, Matthew L.

Get full text

Abstract PS06-07: Liquid biopsy determination of HER2 status in breast cancer: results from a novel epigenomic platform by Parsons, Heather, Baca, Sylvan, D'Ippolito, Anthony, Jeong, Hyun-Hwan, Smith, Kalie, Tarantino, Paolo, Hughes, Melissa, Sendrick, Kerry, Painter, Corrie, Seo, Ji-Heui, Grant, Elizabeth, Guess, Jamey, Davidsohn, Matthew, Lakshminarayanan, Gitanjali, Strauss, Sarah, Savignano, Hunter, Canniff, John, Fortunato, Brad, Eaton, Matthew, Choueiri, Toni, Tolaney, Sara, Freedman, Matthew, Lin, Nancy

“…Abstract Background: Tumor HER2 status remains a critical predictive biomarker for patients with breast cancer given the availability of highly effective…”
Get full text